FeesSafety
Pluang+

TD Cowen keeps Buy on Gilead as HIV and oncology drive strong growth outlook

Analyst Insights
19 Nov 2026, 02:04 WIB
Alex Lavoie
View Source
Bullish
TD Cowen keeps Buy on Gilead as HIV and oncology drive strong growth outlook

TD Cowen reaffirmed its Buy rating on Gilead Sciences, highlighting the company's strong growth driven by HIV and oncology treatments. Gilead reported its best growth in over a decade in Q3 2026 and is expanding into inflammation treatments. The company aims for 10-11% base business growth by 2026 and expects continued earnings growth despite some pricing challenges. This outlook supports investor confidence in Gilead's diversified pipeline and long-term prospects.

Gilead Sciences is trading at USD 169.02 on Pluang, down 0.73% in the last day, with a market cap of $211.18 billion. Most investors on Pluang are selling, with 99% of order activity as of Nov 19, 2026 02:51 WIB.

More News (GILD)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App